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Anthracyclines (ANT) have been among the first line treatments for many types of cancer, 
including acute myeloid leukemia, for decades. These chemotherapeutic agents target 
topoisomerase II, interfere with DNA and RNA synthesis by intercalation, and induce apoptosis 
by forming reactive oxygen species. As with many other chemotherapeutics, administration of 
ANT is associated with a range of adverse effects, particularly cardiotoxicity and resistance. 
The culprit responsible for this cardiotoxicity is the hydroxy metabolite of ANT, formed by 
reduction of the carbonyl group at position 13. This metabolite is also considerably less 
cytotoxic; cancer cells excessively metabolize ANT, thus developing resistance to their effects. 
Enzymes involved in the ANT reductions are NADPH dependant carbonyl reducing enzymes, 
primarily from aldo-keto reductase and short-chain dehydrogenase/reductase superfamilies. 
These enzymes are frequently over-expressed in cancer cells and they might be an attractive 
target of novel chemotherapeutics. Inhibitory effects towards CRE have already been observed 
in some cyclin-dependent kinase inhibitors, phosphoinositide 3-kinase inhibitors, poly(ADP-
ribose)polymerase inhibitors, and Bruton's tyrosine kinase (BTK) inhibitors. Following these 
findings, the effects of a BTK inhibitor evobrutinib (Evo) were tested on a selection of CRE in 
vitro within this thesis. Selected enzymes were incubated with substrate daunorubicin and 
inhibitor Evo. Using the UHPLC system and GraphPad program, the most inhibited enzymes 
were determined, and their IC50 values were calculated. For the most inhibited enzyme 
(AKR1C3) Ki, type of inhibition and type of bonding were determined. Evo is a novel BTK 
inhibitor, non-competitively inhibiting the enzyme AKR1C3 (IC50= 1,721 µM; Ki= 1,81 µM), 
therefore counteracting the reduction of daunorubicin to its cardiotoxic and less effective 
metabolite daunorubicinol. AKR1C3 is one of the chief enzymes reducing ANT, and its 
inhibition may be the key to solving the problems associated with ANT administration.  
 
